InspireMD (STU:II2) Moat Score: 2/10 (As of Jun. 29, 2026)


STU:II2 InspireMD Inc STU:II2
47 GF Score
Price €0.60
GF Value €1.50
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD Moat Score?

InspireMD STU:II2 +5.26% 47 Moat Score is 2 as of Jun. 29, 2026. GuruFocus rates STU:II2 with a GF Score™ of 47/100 and a GF Value™ of €1.50 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 846 Medical Devices & Instruments companies, InspireMD ranks better than 68.2% on this metric.

InspireMD has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

InspireMD has No Moat: InspireMD Inc lacks significant market leadership and customer switching costs. The company operates in a competitive medical device industry with limited brand strength and no significant cost advantages or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes InspireMD might have No Moat - Very weak/transient advantages.

InspireMD  (STU:II2) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

InspireMD Moat Score Related Terms

STU:II2 vs TELA, BDMD, PAVM: Moat Score Comparison

For the Medical Devices subindustry, InspireMD's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InspireMD Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Moat Score distribution charts can be found below:

* The bar in red indicates where InspireMD's Moat Score falls into.


STU:II2
47GF Score
InspireMD Inc STU:II2
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
InspireMD (STU:II2) has a Moat Score of 2 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, InspireMD ranks #269 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 31.8%.
Is InspireMD's Moat Score too high?
InspireMD's current Moat Score is 2. Based on the distribution chart, InspireMD ranks #269 out of 846 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, InspireMD has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Moat Score compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #269 out of 846 companies for Moat Score. This puts InspireMD in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. InspireMD's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.50, compared to a current price of €0.60 — trading 60% below its estimated fair value. The current Moat Score is 2. InspireMD's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For InspireMD (STU:II2), the current Moat Score is 2 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.60 is trading 60% below its estimated GF Value™ of €1.50. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • Moat Score: 2
  • GF Value™: €1.50 vs. price of €0.60 (60% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
47GF Score

Get the complete analysis for STU:II2

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price
€1.50
GF Value